Payment overview · 2025
General Payments
$1,039.12
45 reported records · 16 companies
Healthcare provider profile · identity verified
Jack Rubin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · LOS ALAMITOS, CA · NPI 1700882479
Verified facts
What the public records show
CMS Open Payments records show Jack Rubin, M.D. received $1,039.12 in general payments during 2025 across 45 reported records.
AKEBIA THERAPEUTICS INC accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 404 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $190.66 | 18.4% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $170.73 | 16.4% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $83.90 | 8.1% | 4 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $80.86 | 7.8% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $77.20 | 7.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.22 | 6.5% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.71 | 6.4% | 3 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $58.03 | 5.6% | 3 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.70 | 4.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.40 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.20 | 3.1% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.96 | 3.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $29.29 | 2.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.85 | 2.8% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $23.94 | 2.3% | 1 | 2025 |
| Siemens Medical Solutions USA, Inc. | Unresolved — no canonical attribution shown | $14.47 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,039.12 | 45 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $190.66 | 8 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $146.06 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $83.90 | 4 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $80.86 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $77.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.22 | 3 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $66.71 | 3 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $58.03 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.20 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.85 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $25.35 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $24.67 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Cios Alpha Normalized: cios alpha |
Device | Siemens Medical Solutions USA, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 277 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 404 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 280 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
277 | 54 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
280 | 53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
404 | 68 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 57 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 728 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 545 | 112 |
| Jardiance | Empagliflozin | 404 | 68 |
| Losartan Potassium | Losartan Potassium | 376 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 74 |
| Gabapentin | Gabapentin | 318 | 57 |
| Eliquis | Apixaban | 303 | 34 |
| Kerendia | Finerenone | 280 | 53 |
| Farxiga | Dapagliflozin Propanediol | 277 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 250 | 55 |
| Ozempic | Semaglutide | 249 | 57 |
| Furosemide | Furosemide | 245 | 54 |
| Metformin Hcl | Metformin Hcl | 244 | 49 |
| Carvedilol | Carvedilol | 241 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 52 |
| Lisinopril | Lisinopril | 211 | 41 |
| Chlorthalidone | Chlorthalidone | 201 | 31 |
| Trulicity | Dulaglutide | 197 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 28 |
| Trazodone Hcl | Trazodone Hcl | 182 | 28 |
| Potassium Chloride | Potassium Chloride | 177 | 28 |
| Famotidine | Famotidine | 174 | 33 |
| Donepezil Hcl | Donepezil Hcl | 173 | 30 |
| Omeprazole | Omeprazole | 154 | 31 |
| Spironolactone | Spironolactone | 149 | 41 |
| Mounjaro | Tirzepatide | 148 | 20 |
| Risperidone | Risperidone | 147 | suppressed |
| Prednisone | Prednisone | 140 | 30 |
| Allopurinol | Allopurinol | 139 | 31 |
| Ondansetron Hcl | Ondansetron Hcl | 134 | 46 |
| Levetiracetam | Levetiracetam | 127 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 40 |
| Sevelamer Carbonate | Sevelamer Carbonate | 120 | 33 |
| Tramadol Hcl | Tramadol Hcl | 117 | 38 |
| Prosol | Parenteral Amino Acid 20% No.1 | 109 | suppressed |
| Torsemide | Torsemide | 108 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 26 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 106 | 12 |
| Clonidine Hcl | Clonidine Hcl | 104 | 31 |
| Januvia | Sitagliptin Phosphate | 103 | 12 |
| Memantine Hcl | Memantine Hcl | 103 | 16 |
| Alprazolam | Alprazolam | 101 | 16 |
| Simvastatin | Simvastatin | 100 | 25 |
| Alendronate Sodium | Alendronate Sodium | 99 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 23 |
| Nifedipine Er | Nifedipine | 96 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 19 |
| Baclofen | Baclofen | 89 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 18 |
| Xarelto | Rivaroxaban | 86 | suppressed |
| Bumetanide | Bumetanide | 83 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 82 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 80 | suppressed |
| Clinisol | Parenteral Amino Acid 15% No.5 | 80 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 15 |
| Mirtazapine | Mirtazapine | 77 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 20 |
| Sertraline Hcl | Sertraline Hcl | 75 | 21 |
| Megestrol Acetate | Megestrol Acetate | 74 | 23 |
| Montelukast Sodium | Montelukast Sodium | 74 | 16 |
| Azithromycin | Azithromycin | 72 | 48 |
| Divalproex Sodium | Divalproex Sodium | 70 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 69 | 19 |
| Finasteride | Finasteride | 64 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 16 |
| Midodrine Hcl | Midodrine Hcl | 63 | 21 |
| Topiramate | Topiramate | 62 | suppressed |
| Lactulose | Lactulose | 61 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 59 | 15 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Latanoprost | Latanoprost | 57 | 11 |
| Entresto | Sacubitril/Valsartan | 55 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | suppressed |
| Pregabalin | Pregabalin | 53 | 12 |
| Epogen | Epoetin Alfa | 51 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 51 | 18 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 48 | 17 |
| Glipizide | Glipizide | 48 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Xphozah | Tenapanor Hcl | 45 | suppressed |
| Calcium Acetate | Calcium Acetate | 44 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Sucralfate | Sucralfate | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Clonidine | Clonidine | 42 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Nystatin | Nystatin | 41 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 27 |
| Enoxaparin Sodium | Enoxaparin Sodium | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | suppressed |
| Cephalexin | Cephalexin | 36 | 31 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Timolol Maleate | Timolol Maleate | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 32 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 25 |
| Hydrocortisone | Hydrocortisone | 30 | 11 |
| Lorazepam | Lorazepam | 30 | suppressed |
| Phenytoin | Phenytoin | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 14 |
| Invokana | Canagliflozin | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 12 |
| Diazepam | Diazepam | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Lidocaine | Lidocaine | 26 | 11 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Procrit | Epoetin Alfa | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Alogliptin | Alogliptin Benzoate | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Pentoxifylline | Pentoxifylline | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 17 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 17 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,039.12 · 45 records | AKEBIA THERAPEUTICS INC | Cios Alpha, Empaveli, FARXIGA, FUROSCIX, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, LUPKYNIS, Ozempic, RAYALDEE, TARPEYO, VOYXACT, Vafseo | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error